JP2016502526A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016502526A5 JP2016502526A5 JP2015542769A JP2015542769A JP2016502526A5 JP 2016502526 A5 JP2016502526 A5 JP 2016502526A5 JP 2015542769 A JP2015542769 A JP 2015542769A JP 2015542769 A JP2015542769 A JP 2015542769A JP 2016502526 A5 JP2016502526 A5 JP 2016502526A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- binding antibody
- composition according
- subject
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261727334P | 2012-11-16 | 2012-11-16 | |
| US61/727,334 | 2012-11-16 | ||
| PCT/US2013/070042 WO2014078502A1 (en) | 2012-11-16 | 2013-11-14 | Use of il-1 beta binding antibodies for treating peripheral arterial disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016502526A JP2016502526A (ja) | 2016-01-28 |
| JP2016502526A5 true JP2016502526A5 (OSRAM) | 2016-12-28 |
Family
ID=49679654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015542769A Pending JP2016502526A (ja) | 2012-11-16 | 2013-11-14 | 末梢動脈疾患を処置するためのＩＬ−１β結合抗体の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US10000565B2 (OSRAM) |
| EP (1) | EP2919811B1 (OSRAM) |
| JP (1) | JP2016502526A (OSRAM) |
| AU (1) | AU2013344796B2 (OSRAM) |
| CA (1) | CA2891556A1 (OSRAM) |
| WO (1) | WO2014078502A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018516931A (ja) | 2015-06-04 | 2018-06-28 | ノバルティス アーゲー | 末梢動脈疾患を処置するためのｉｌ−１ベータ結合抗体の使用 |
| US20180291097A1 (en) * | 2015-06-04 | 2018-10-11 | Craig Basson | Use of il-1 beta binding antibodies to treat peripheral arterial disease |
| CA2994043A1 (en) | 2015-07-31 | 2017-02-09 | Glaxosmithkline Intellectual Property Development Limited | Antibody variants |
| CA3005989C (en) * | 2015-11-24 | 2025-11-18 | University Of Georgia Research Foundation, Inc. | VIRUS PRODUCTION IN A CELL CULTURE |
| JP2019521161A (ja) * | 2016-07-21 | 2019-07-25 | ノバルティス アーゲー | 肺サルコイドーシスの症状を治療するまたは軽減するためのＩＬ−１β結合抗体カナキヌマブの使用 |
| EP3551034A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| US20200315540A1 (en) | 2016-12-14 | 2020-10-08 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor |
| EP3717006A1 (en) * | 2017-09-13 | 2020-10-07 | Novartis AG | Use of il-1b binding antibodies for the treatment of alcoholic hepatitis |
| US20210347915A1 (en) * | 2018-09-20 | 2021-11-11 | Phasebio Pharmaceuticals, Inc. | Methods of reversing ticagrelor activity |
| WO2020106704A2 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| CN112402359A (zh) * | 2020-11-04 | 2021-02-26 | 深圳前海鹰岗生物科技有限公司 | 一种抑制细胞炎症因子治疗痛风急性发作的聚合物微针及制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| RU2554747C9 (ru) * | 2006-12-20 | 2015-10-20 | Ксома (Сша) Ллс | Способы лечения il-1бета-зависимых заболеваний |
| CA2722620A1 (en) | 2008-03-26 | 2009-10-01 | Orthologic Corp. | Method of treating peripheral arterial disease |
| SG191639A1 (en) * | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| EP2297208A4 (en) * | 2008-06-03 | 2012-07-11 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
| EP2341936A4 (en) * | 2008-09-05 | 2012-07-25 | Xoma Technology Ltd | METHOD FOR TREATING OR PREVENTING IL-1ß-CONTAINED ILLNESSES |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| CA2749966A1 (en) | 2009-01-29 | 2010-08-05 | Abbott Laboratories | Il-1 binding proteins |
| BRPI1011228A2 (pt) * | 2009-05-29 | 2019-09-24 | Xoma Technology Ltd. | métodos para reduzir um evento cardiovascular em um indivíduo, mortalidade seguindo um evento cardiovascular em um indivíduo e restenose em um indivíduo seguindo um procedimento de revascularização, e, para tratar um evento cardiovascular em um indivíduo e hipertensão aguda em um indivíduo. |
| KR20120104542A (ko) * | 2009-10-15 | 2012-09-21 | 아보트 러보러터리즈 | Ｉｌ?１ 결합 단백질 |
| EP2601218A4 (en) * | 2010-08-03 | 2015-02-18 | Abbvie Inc | VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF |
| AU2012316083A1 (en) | 2011-09-30 | 2014-04-17 | Novartis Ag | Use of IL-1 beta binding antibodies |
-
2013
- 2013-11-14 WO PCT/US2013/070042 patent/WO2014078502A1/en not_active Ceased
- 2013-11-14 US US14/442,536 patent/US10000565B2/en active Active
- 2013-11-14 CA CA2891556A patent/CA2891556A1/en not_active Abandoned
- 2013-11-14 AU AU2013344796A patent/AU2013344796B2/en not_active Ceased
- 2013-11-14 JP JP2015542769A patent/JP2016502526A/ja active Pending
- 2013-11-14 EP EP13798486.0A patent/EP2919811B1/en not_active Not-in-force
-
2018
- 2018-05-21 US US15/984,993 patent/US20180258166A1/en not_active Abandoned
-
2019
- 2019-06-21 US US16/448,341 patent/US20200148759A1/en not_active Abandoned
-
2021
- 2021-04-15 US US17/231,400 patent/US20210317202A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016502526A5 (OSRAM) | ||
| Wiegand et al. | Treatment of lymphatic malformations with the mTOR inhibitor sirolimus: a systematic review | |
| KR102446673B1 (ko) | 암 치료를 위한 약물의 제조에 있어서 항-pd-1 항체 및 vegfr 억제제의 조합의 용도 | |
| Accardi et al. | Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: impact on myeloma‐induced alterations of bone remodeling | |
| ES2644022T3 (es) | Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso | |
| RU2708374C2 (ru) | Комбинированная терапия для лечения рака | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| JP2015187125A5 (OSRAM) | ||
| JP2015530867A5 (OSRAM) | ||
| JP2017528427A5 (OSRAM) | ||
| JP2017537105A5 (OSRAM) | ||
| US20080008716A1 (en) | Combined Pharmaceutical Composition Comprising an Anti-4-1BB Monoclonal Antibody and Chemotherapeutic Anti-Cancer Agent for Preventing and Treating Cancer Disease | |
| KR20180018695A (ko) | 항암제 | |
| JP2023071715A (ja) | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 | |
| JP2013506684A5 (OSRAM) | ||
| JP2016537380A5 (OSRAM) | ||
| KR20240090993A (ko) | 류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체 | |
| RU2011150619A (ru) | Комбинация ингибитора фосфоинозитид-3-киназы и противодиабетического соединения | |
| Frappaz et al. | Phase 1 study of dalotuzumab monotherapy and ridaforolimus–dalotuzumab combination therapy in paediatric patients with advanced solid tumours | |
| RU2013108390A (ru) | Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека | |
| Topal et al. | Scleroderma therapy: clinical overview of current trends and future perspective | |
| JP2019533715A5 (OSRAM) | ||
| RU2018114457A (ru) | Лечение syd985 пациентов с t-dm1 рефрактерным раком | |
| CN112955148B (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 | |
| US20240173403A1 (en) | Combination of AXL Antibodies and ACE Inhibitors in the Treatment of Fibrosis |